Thyroid hormone, immunoglobin and complements for predicting hepatocellular carcinoma development in patients with hepatitis B virus-related liver cirrhosis

Table 3 Characteristics of patients in the internal subgroup

Variables	Compensated cirrhosis (n = 60)	Decompensated cirrhosis (n = 40)	Z or χ²	P value
Age (years)	50.1 (45.3, 55)	60.2 (55, 66.8)	4.247	< 0.01
Male	38 (63.3)	29 (72.5)	0.912	0.34
Hepatocellular carcinoma	2 (3.3)	10 (25)	10.669	< 0.01
Diabetes	12 (20)	16 (40)	4.762	0.03
Alanine transaminase (U/L)	105.5 (21, 95.3)	52.1 (21.3, 59.5)	1.116	0.27
Aspartate transaminase (U/L)	71.3 (23.3, 56.5)	57.5 (29.5, 57.3)	1.165	0.24
Gamma-glutamyl transpeptidase (U/L)	74.2 (26.3, 82)	92.4 (35.5, 123)	1.530	0.13
Total bilirubin (µmol/L)	21 (14.9, 23.7)	35.3 (18.7, 47.7)	3.912	< 0.01
Albumin (g/L)	41.9 (39.8, 45.1)	34.3 (29.5, 40.1)	5.717	< 0.01
Creatinine (µmol/L)	79.4 (71.4, 89.5)	87.4 (66.8, 88.7)	0.310	0.76
International normalized ratio	1.1 (0.99, 1.1)	1.3 (1.1, 1.5)	5.365	< 0.01
Platelet (E+09/L)	122.1 (84.5, 153.5)	87.2 (50.3, 107.8)	3.652	< 0.01
Total triiodothyronine (nmol/L)	1.8 (1.6, 2.0)	1.3 (1.1, 1.5)	6.414	< 0.01
Total tetraiodothyronine (nmol/L)	125.3 (107.6, 140.8)	108.3 (90.9, 126.5)	2.698	< 0.01
Free triiodothyronine (pmol/L)	5.1 (4.6, 5.5)	4.3 (3.8, 4.9)	4.655	< 0.01
Free tetraiodothyronine (pmol/L)	11.3 (10.3, 12.3)	11.3 (9.6, 12.8)	0.127	0.90
Thyroid-stimulating hormone (μIU/mL)	1.6 (1.1, 1.9)	1.8 (1.1, 2.2)	0.454	0.65
IgM (g/L)	1.4 (0.9, 1.7)	1.6 (1.0, 2.0)	1.168	0.24
IgA (g/L)	2.6 (2.0, 3.1)	3.9 (2.6, 5.1)	4.208	< 0.01
IgG (g/L)	15.0 (12.3, 16.5)	17.4 (13.9, 19.8)	2.712	< 0.01
Complement C3 (g/L)	0.9 (0.7, 0.9)	0.7 (0.6, 1.0)	3.087	< 0.01
Complement C4 (g/L)	0.2 (0.1, 0.3)	0.1 (0.1, 0.2)	2.915	< 0.01
Duration of follow-up (months)	32 (25.3, 36.8)	27.9 (23, 35)	1.972	0.05

Comparison was conducted by a Mann-Whitney U test (median and interquartile range) for continuous variables, and χ² test for categorial values. Ig: Immunoglobulin.